Stockreport

Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference

Catabasis Pharmaceuticals, Inc.  (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview
PDF -- Patient Identification Nearing Completion for Global Phase 3 PolarisDMD Trial for Edasalonexent in Duchenne Muscular Dystrophy -- CAMBRIDGE, Mass.--(BUSINESS WIRE) [Read more]